-
Gaps in Cancer Screening Uptake in Ireland: Trends, Barriers and Policy Implications
Sep 9, 2025, 16:22 PM -
Real-World Healthcare Resource Utilization and Related Costs Associated With Lung Cancer in the Brazilian Private Market
Sep 9, 2025, 16:22 PM -
Budgetary Impact of Ultra-Rare Diseases in Brazil: A Review of Decisions From the Past Five Years
Sep 9, 2025, 16:22 PM -
Economic and Clinical Impact of Older Adult Vaccination With the Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Mexico
Sep 9, 2025, 16:22 PM -
KRAS Alterations in Advanced Non-Small Cell Lung Cancer (NSCLC): Temporal Trends in Testing Patterns and Targeted Treatment Use Across Europe Between 2018 and 2024
Sep 9, 2025, 16:22 PM -
Registration and Access to Orphan Medicines in Türkiye: A Comparative Study With Poland and Germany
Sep 9, 2025, 16:22 PM -
An Interactive Tool to Select Indirect Treatment Comparison Methods for Rapid Feasibility Assessment
Sep 9, 2025, 16:22 PM -
Do Short-Term Outcome-Based Payments for Treatments Provide the Same Incremental Net Benefit As List Price Discounts?
Sep 9, 2025, 16:22 PM -
What Makes a Medicine Innovative? A Literature Review of Evaluation Frameworks
Sep 9, 2025, 16:22 PM -
Overall Survival Adjusted for Subsequent Treatments: A Review of Health Technology Assessments
Sep 9, 2025, 16:22 PM -
Exploring Nonproportional Hazards Multi-Level Network Meta-Regression (ML-NMR) for Survival Extrapolations in Oncology
Sep 9, 2025, 16:22 PM -
What Affects Quality of Life Most in Oral Cancer Therapy? A Pilot Study of Adherence and Side Effects
Sep 9, 2025, 16:22 PM -
Model Behavior: A Health Economics Checklist for Sales Models
Sep 9, 2025, 16:22 PM -
Exploring Off-Label Drug Coding Trends in French Hospitals: A Descriptive and Stratified Analysis 2020-2024
Sep 9, 2025, 16:22 PM -
Gender Inequalities in Aortic and Mitral Valve Replacement and Repair Procedures in Germany
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization and Survival of Patients With HR+/HER2-negative Metastatic Breast Cancer After Treatment With CDK4/6-Inhibitors in Finland
Sep 9, 2025, 16:22 PM -
Comparing Clinical Benefit Criteria in Health Technology Assessment of Oncology Drugs in the Netherlands and Europe: Driving Real Value or Inequal Access?
Sep 9, 2025, 16:22 PM -
Real-World Treatment Patterns Among Patients With Relapsed or Refractory (R/R) NPM1 Mutated (NPM1m) Acute Myeloid Leukemia (AML) in the United States (US)
Sep 9, 2025, 16:22 PM -
Mapping the Landscape of Digital Healthcare Services Delivered by Specialized Oncology Hospitals in China: Qualitative Analytical Study
Sep 9, 2025, 16:22 PM -
Analysis of ATC Equivalent Group and Therapeutic Reference Code Distributions Based on Drug Price and Reimbursement Lists in Türkiye Between 2020 and 2025
Sep 9, 2025, 16:22 PM
